Septerna, Inc. Financing Cash Flow
Septerna, Inc. (SEPN) reported Financing Cash Flow of $17.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- Septerna, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $16.82M, a 4862.83% increase year-over-year.
- Septerna, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $333.00K, a 404.55% increase year-over-year.
- Septerna, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.02M, a 99.66% decline year-over-year.
- Septerna, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $263.00K.
- Septerna, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $1.69M, a 99.55% decline from fiscal 2024.
- Septerna, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $377.78M, a 406.95% increase from fiscal 2023.
- Septerna, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $74.52M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $17.16M 10-Q · filed 2026-08-10 | $18.18M derived: sum of 3 quarters · filed 2026-08-10 | $18.44M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $333.00K 10-Q · filed 2026-05-11 | $1.35M derived: sum of 2 quarters · filed 2026-05-11 | $1.62M derived: sum of 3 quarters · filed 2026-05-11 | $1.96M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.28M derived: sum of 2 quarters · filed 2026-03-09 | $1.62M derived: sum of 3 quarters · filed 2026-08-10 | $1.69M 10-K · filed 2026-03-09 |
| 2025-09-30 | $263.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $602.00K derived: sum of 2 quarters · filed 2026-08-10 | $668.00K 10-Q · filed 2025-11-10 | $304.82M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $339.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $405.00K 10-Q · filed 2026-08-10 | $304.56M derived: sum of 3 quarters · filed 2026-08-10 | $303.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $66.00K 10-Q · filed 2026-05-11 | $304.22M derived: sum of 2 quarters · filed 2026-05-11 | $302.89M derived: sum of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | $304.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $302.83M derived: sum of 2 quarters · filed 2026-03-09 | $377.78M 10-K · filed 2026-03-09 | |
| 2024-09-30 | -$1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $73.63M 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $74.95M 10-Q · filed 2025-08-11 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $74.52M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $74.52M 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |